Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H3GK
|
||||
Former ID |
DIB005031
|
||||
Drug Name |
Autologous cell based gene therapy
|
||||
Synonyms |
Autologous cell based gene therapy (pulmonary hypertension)
|
||||
Indication | Pulmonary hypertension [ICD9: 416; ICD10:I27.0, I27.2] | Phase 1 | [534588] | ||
Company |
University of Toronto
|
||||
Target and Pathway | |||||
Target(s) | Nitric-oxide synthase, endothelial | Target Info | Modulator | [526424] | |
BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
NetPath Pathway | Wnt Signaling Pathway | ||||
Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
Thromboxane A2 receptor signaling | |||||
SHP2 signaling | |||||
VEGFR1 specific signals | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
PAR1-mediated thrombin signaling events | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.